• $183.4M
    Market Cap
  • 681.51%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 86
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Wereldhave, through Wereldhave Belgium, acquires supermarket unit and completes ownership of shopping center Ville2 in Charleroi

Wereldhave Belgium has acquired a supermarket anchor unit in shopping center Ville2 in Charleroi, achieving 100% ownership of the property. The acquisition was financed through newly issued Wereldhave N.V. shares at market value and will have a slightly positive impact on the group's LTV ratio, reducing it by 10 basis points to 42.4%.

03/11/2026, 2:00 AM • GlobeNewswire

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

Equillium will host a virtual key opinion leader event discussing unmet needs in ulcerative colitis treatment, featuring experts who will explore the potential of AhR modulation and the company's EQ504 therapeutic approach.

10/22/2025, 8:00 AM • GlobeNewswire

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025

Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.

09/03/2025, 7:30 AM • The Motley Fool

Peers

Statistics

More
Day Range
$2.23
$2.99
$2.79
1-Year Range
$0.29
$3.08
$2.79
Latest Close$2.79
Change
-$0.29 (-10.39%)
Volume2,771,729
Market Cap$183.4M
Shares Outstanding63.2M
P/E (TTM)-11.00
Diluted EPS (TTM)-$0.26
Enterprise Value$122.0M

Information as of 06/02/2026

Company Profile

$183.4M
Market Cap
-$19.1M
Net Income
Sector: Healthcare
Industry: Biotechnology
2223 Avenida De La Playa, La Jolla, CA, United States, 92037
858 240 1200

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Key Executives

  • Bruce D. Steel
  • Stephen Connelly
  • Christine Zedelmayer
  • Penny Tom
  • Lisette Acevedo

Current Ownership Distribution

  • Institutions249.4M (82.09%)
  • Mutual Funds44.6M (14.67%)
  • Insiders9.8M (3.24%)
  • Other0 (0.00%)